France Respiratory Devices Market

France Respiratory Devices Market Analysis

The France Respiratory Devices Market is expected to register a CAGR of 6.5% during the forecast period.

• Major respiratory devices such as masks, ventilators, nebulizers, CPAP, BiPAP, and oxygen concentrators were in great demand during the COVID-19 pandemic to prevent and manage infection in the country. However, with the easing of COVID-19 restrictions on wearing masks and the decline in COVID-19 cases, the demand for respiratory devices is anticipated to decrease. For instance, in March 2022, France lifted most COVID-19 restrictions, abolishing the need to wear face masks in most settings and allowing people who aren't vaccinated back into restaurants, sports arenas, and other venues. This lifted COVID-19 restrictions in the country decreases the demand for respiratory disposables like masks, which are expected to have an adverse impact on the market over the coming years.
• The rise in the number of respiratory disease cases like chronic obstructive pulmonary disease (COPD), tuberculosis, asthma, and pneumonia remains the major driver of the industry. For instance, as per the report published by Plos One in January 2021, in France, there are 2.6 million people who have chronic obstructive pulmonary disease (COPD) in 2021, and by 2025, that number is expected to rise to 2.8 million. This shows the increasing prevalence of respiratory disease, which is expected to increase the demand for respiratory devices and likely propel the market over the forecast period.
• Furthermore, the new studies on respiratory devices for expanding the applications are expected to drive market growth. For instance, as per the study report published by PLoS One in January 2022, the use of respiratory-connected devices has been emphasized as a crucial new tactic for enhancing patient care during a COPD exacerbation. Hence, the new studies on respiratory devices provide various new applications and likely increase the demand for respiratory devices and are expected to boost the growth of the market over the forecast period.
• However, the high cost of various respiratory devices is expected to hinder market growth over the forecast period.

France Respiratory Devices Market Trends

Spirometers Segment is Expected to Have Significant Growth in the Market Over the Forecast Period

• A spirometer is an apparatus for measuring the volume of air inspired and expired by the lungs. Spirometry is the recommended test to confirm asthma. The main factor attributing to the growth of the spirometer segment is the increasing burden of respiratory disorders, such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD), across the country. The wide application of spirometers makes it easier for patients to use this device and is, thus, increasingly adopted in hospitals and home care settings. The high burden of cigarette smoking among people in France increases the risk of various respiratory diseases, which raises the demand for diagnosis using a spirometer and drives the market to grow.
• The high burden of obstructive respiratory diseases drives the market through this segment. For instance, according to the study report published by Plos One in November 2022, France had the highest rate of asthma prevalence at 13.50%. This shows the high burden of asthma in France, which increases the demand for diagnosis using a spirometer and is expected to drive the market to grow over the study period. In addition, the significant advancements in the field of spirometry include the development of small portable spirometers and the increasing accuracy and acceptability, which are expected to fuel the market growth over the forecast period.

Inhalers Under Therapeutic Devices Segment is Expected to Have Highest CAGR in the Market Over the Forecast Period

• A device known as an inhaler allows a person to breathe the medicine directly into their lungs. The patient breathes in a mist or spray that contains the medication. Inhalers are portable medical devices used to administer medication to the respiratory tract in cases of asthma, tuberculosis (TB), and chronic obstructive pulmonary disease (COPD). Hence, the high burden of these diseases raises the demand for inhalers in France, which is expected to drive the market through this segment.
• According to the data published by 123Medical.fr in August 2022, in France, chronic obstructive pulmonary disease (COPD) causes 3% of fatalities, and over four million French citizens suffer from asthma, which needs inhalational therapy for treating several respiratory conditions. Several medicines like bronchodilators are used in inhalers, and the high burden of these respiratory diseases increases the demand for medications through inhalers and is expected to boost the market over the study period.
• In addition, the high burden of smoking increases the risk of respiratory diseases and increases the demand for inhalers for treatment. For instance, as per the report by Vie-publique.fr in December 2022, the average cigarette smoking among the country's population is estimated to be 25.3% in 2021. This shows the substantial impact of smoking, heightening the vulnerability to respiratory illnesses and spurring the demand for inhaler medications. This trend is anticipated to propel market growth within this segment throughout the forecast period.

France Respiratory Devices Industry Overview

The France respiratory devices market is competitive with several market players. Some of the market players in the market are Drägerwerk AG & Co. KGaA, Drive Devilbiss International, Fisher & Paykel Healthcare Limited, GE Healthcare, GSK plc, Invacare Corporation, Koninklijke Philips N.V, Medtronic PLC, and ResMed Inc.

France Respiratory Devices Market Leaders

France Respiratory Devices Market News

• November 2022: Biosency entered into a strategic partnership with ResMed. Under this collaboration, ResMed will distribute BIOSENCY's telemonitoring device, Bora-Care, in France. This device is aimed at supporting homecare patients dealing with respiratory insufficiency.
• October 2022: Medtronic plc revealed its plan to separate its Patient Monitoring and Respiratory Interventions businesses (NewCo) from the company's broader Medical Surgical Portfolio. The anticipated timeline for this separation is within the next 12 to 18 months.